Rucaza contains rucaparib, a targeted anti-cancer medicine classified as a PARP inhibitor. It is primarily used in the treatment of certain types of ovarian, fallopian tube, and peritoneal cancers. Rucaza is designed for patients whose tumours are associated with mutations in the BRCA gene, especially those who have already responded to platinum-based chemotherapy.

Mechanism of Action
Rucaparib works by blocking the action of PARP enzymes, which help repair damaged DNA in cells. In cancer cells with BRCA mutations, this repair mechanism is already weakened. By further inhibiting PARP, rucaparib causes the cancer cells to accumulate DNA damage, leading to their death while sparing most normal cells.

Uses
Rucaza is indicated for the maintenance treatment of adult patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. It may also be used as a treatment option for patients with BRCA-mutated cancers, particularly when other treatments have become less effective.

Adverse Effects
Common side effects include nausea, fatigue, constipation, loss of appetite, and changes in taste. It can also lead to anaemia, low platelet or white blood cell counts, and liver enzyme elevations. Some patients may experience abdominal discomfort or shortness of breath. Regular blood tests are important during treatment to monitor for any serious changes and ensure safe use.